Fortunately, these efforts can exploit the ongoing development of new agonists, partial agonists, and PAMs targeting α7-nAChR that are presently aimed at treating CNS diseases such as Alzheimer’s disease, Parkinson’s disease, and schizophrenia [152]. Here, CHRNA7 is linked to Alzheimer disease.